Skip to main content
Top
Published in: BMC Infectious Diseases 1/2006

Open Access 01-12-2006 | Research article

Development of a Health-Related Quality of Life Questionnaire (HRQL) for patients with Extremity Soft Tissue Infections (ESTI)

Authors: Aric J Storck, Kevin B Laupland, Ronald R Read, Manuel W Mah, John M Gill, Deborah Nevett, Thomas J Louie

Published in: BMC Infectious Diseases | Issue 1/2006

Login to get access

Abstract

Background

Past clinical trials of antimicrobial treatment in soft tissue infections have focused on non-standardized clinical and physiological outcome variables, and have not considered the subjective experience of patients. The objective of this study was to develop a health-related quality of life questionnaire (HRQL) for patients with extremity soft tissue infections (ESTI) for future use in clinical trials.

Methods

The design of this study followed published guidelines and included item generation, item reduction, and questionnaire preparation. Study subjects were consenting English-speaking adults with acute ESTI requiring prescription of at least two days of outpatient intravenous antibiotic therapy.

Results

A list of 49 items that adversely impact the quality of life of patients with ESTI was generated by literature review, informal health professional feedback, and semi-structured interviews with twenty patients. A listing of these items was then administered to 95 patients to determine their relative importance on quality of life. A questionnaire was prepared that included the twenty most important items with a 5-point Likert scale response. Questionnaire domains included physical symptoms, problems performing their activities of daily living, impairment of their emotional functioning, and difficulties in their social interactions as related to their ESTI. The final questionnaire was pre-tested on a further ten patients and was named the ESTI-Score.

Conclusion

The ESTI-Score is a novel instrument designed to quantify the impact of ESTI on quality of life. Future study is required to determine its validity and responsiveness before use as an outcome measure in clinical trials.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gottlieb T, Atkins BL, Shaw DR: 7: Soft tissue, bone and joint infections. Med J Aust. 2002, 176: 609-615.PubMed Gottlieb T, Atkins BL, Shaw DR: 7: Soft tissue, bone and joint infections. Med J Aust. 2002, 176: 609-615.PubMed
2.
go back to reference Stulberg DL, Penrod MA, Blatny RA: Common bacterial skin infections. Am Fam Physician. 2002, 66: 119-124.PubMed Stulberg DL, Penrod MA, Blatny RA: Common bacterial skin infections. Am Fam Physician. 2002, 66: 119-124.PubMed
3.
go back to reference Sharpe JN, Shively EH, Polk HCJ: Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2005, 189: 425-428. 10.1016/j.amjsurg.2005.01.011.CrossRefPubMed Sharpe JN, Shively EH, Polk HCJ: Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2005, 189: 425-428. 10.1016/j.amjsurg.2005.01.011.CrossRefPubMed
4.
go back to reference Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK: Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992, 47 (2): 76-83.CrossRefPubMedPubMedCentral Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK: Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992, 47 (2): 76-83.CrossRefPubMedPubMedCentral
5.
go back to reference Guyatt GH, Naylor CD, Juniper E, Heyland DK, Jaeschke R, Cook DJ: Users' guides to the medical literature. XII. How to use articles about health-related quality of life. Evidence-Based Medicine Working Group. Jama. 1997, 277: 1232-1237. 10.1001/jama.277.15.1232.CrossRefPubMed Guyatt GH, Naylor CD, Juniper E, Heyland DK, Jaeschke R, Cook DJ: Users' guides to the medical literature. XII. How to use articles about health-related quality of life. Evidence-Based Medicine Working Group. Jama. 1997, 277: 1232-1237. 10.1001/jama.277.15.1232.CrossRefPubMed
6.
go back to reference Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK: Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992, 47: 76-83.CrossRefPubMedPubMedCentral Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK: Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992, 47: 76-83.CrossRefPubMedPubMedCentral
7.
go back to reference Juniper EF, Guyatt GH: Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991, 21: 77-83. 10.1111/j.1365-2222.1991.tb00807.x.CrossRefPubMed Juniper EF, Guyatt GH: Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991, 21: 77-83. 10.1111/j.1365-2222.1991.tb00807.x.CrossRefPubMed
8.
go back to reference Cronin L, Guyatt G, Griffith L, Wong E, Azziz R, Futterweit W, Cook D, Dunaif A: Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab. 1998, 83: 1976-1987. 10.1210/jc.83.6.1976.PubMed Cronin L, Guyatt G, Griffith L, Wong E, Azziz R, Futterweit W, Cook D, Dunaif A: Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab. 1998, 83: 1976-1987. 10.1210/jc.83.6.1976.PubMed
9.
go back to reference Flemons WW, Reimer MA: Development of a disease-specific health-related quality of life questionnaire for sleep apnea. Am J Respir Crit Care Med. 1998, 158: 494-503.CrossRefPubMed Flemons WW, Reimer MA: Development of a disease-specific health-related quality of life questionnaire for sleep apnea. Am J Respir Crit Care Med. 1998, 158: 494-503.CrossRefPubMed
10.
go back to reference Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ: Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996, 107: 707-713. 10.1111/1523-1747.ep12365600.CrossRefPubMed Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ: Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996, 107: 707-713. 10.1111/1523-1747.ep12365600.CrossRefPubMed
11.
go back to reference Anderson RT, Rajagopalan R: Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol. 1997, 37: 41-50. 10.1016/S0190-9622(97)70210-X.CrossRefPubMed Anderson RT, Rajagopalan R: Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol. 1997, 37: 41-50. 10.1016/S0190-9622(97)70210-X.CrossRefPubMed
12.
go back to reference Guyatt GH, Bombardier C, Tugwell PX: Measuring disease-specific quality of life in clinical trials. Cmaj. 1986, 134: 889-895.PubMedPubMedCentral Guyatt GH, Bombardier C, Tugwell PX: Measuring disease-specific quality of life in clinical trials. Cmaj. 1986, 134: 889-895.PubMedPubMedCentral
13.
go back to reference Kirshner B, Guyatt G: A methodological framework for assessing health indices. J Chronic Dis. 1985, 38: 27-36. 10.1016/0021-9681(85)90005-0.CrossRefPubMed Kirshner B, Guyatt G: A methodological framework for assessing health indices. J Chronic Dis. 1985, 38: 27-36. 10.1016/0021-9681(85)90005-0.CrossRefPubMed
14.
go back to reference Laupland KB, Gill MJ, Schenk L, Goodwin D, Davies HD: Outpatient parenteral antibiotic therapy: evolution of the Calgary adult home parenteral therapy program. Clin Invest Med. 2002, 25: 185-190.PubMed Laupland KB, Gill MJ, Schenk L, Goodwin D, Davies HD: Outpatient parenteral antibiotic therapy: evolution of the Calgary adult home parenteral therapy program. Clin Invest Med. 2002, 25: 185-190.PubMed
15.
go back to reference Fabian TC, File TM, Embil JM, Krige JE, Klein S, Rose A, Melnick D, Soto NE: Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. Surg Infect (Larchmt). 2005, 6: 269-282. 10.1089/sur.2005.6.269.CrossRef Fabian TC, File TM, Embil JM, Krige JE, Klein S, Rose A, Melnick D, Soto NE: Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. Surg Infect (Larchmt). 2005, 6: 269-282. 10.1089/sur.2005.6.269.CrossRef
16.
go back to reference Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI: The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004, 38: 1673-1681. 10.1086/420818.CrossRefPubMed Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI: The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004, 38: 1673-1681. 10.1086/420818.CrossRefPubMed
17.
go back to reference Siami FS, LaFleur BJ, Siami GA: Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center. Clin Ther. 2002, 24: 59-72. 10.1016/S0149-2918(02)85005-6.CrossRefPubMed Siami FS, LaFleur BJ, Siami GA: Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center. Clin Ther. 2002, 24: 59-72. 10.1016/S0149-2918(02)85005-6.CrossRefPubMed
18.
go back to reference Graham DR, Lucasti C, Malafaia O, Nichols RL, Holtom P, Perez NQ, McAdams A, Woods GL, Ceesay TP, Gesser R: Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis. 2002, 34: 1460-1468. 10.1086/340348.CrossRefPubMed Graham DR, Lucasti C, Malafaia O, Nichols RL, Holtom P, Perez NQ, McAdams A, Woods GL, Ceesay TP, Gesser R: Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis. 2002, 34: 1460-1468. 10.1086/340348.CrossRefPubMed
19.
go back to reference Tarshis GA, Miskin BM, Jones TM, Champlin J, Wingert KJ, Breen JD, Brown MJ: Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Antimicrob Agents Chemother. 2001, 45: 2358-2362. 10.1128/AAC.45.8.2358-2362.2001.CrossRefPubMedPubMedCentral Tarshis GA, Miskin BM, Jones TM, Champlin J, Wingert KJ, Breen JD, Brown MJ: Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Antimicrob Agents Chemother. 2001, 45: 2358-2362. 10.1128/AAC.45.8.2358-2362.2001.CrossRefPubMedPubMedCentral
20.
go back to reference Wasilewski MM, Wilson MG, Sides GD, Stotka JL: Comparative efficacy of 5 days of dirithromycin and 7 days of erythromycin in skin and soft tissue infections. J Antimicrob Chemother. 2000, 46: 255-262. 10.1093/jac/46.2.255.CrossRefPubMed Wasilewski MM, Wilson MG, Sides GD, Stotka JL: Comparative efficacy of 5 days of dirithromycin and 7 days of erythromycin in skin and soft tissue infections. J Antimicrob Chemother. 2000, 46: 255-262. 10.1093/jac/46.2.255.CrossRefPubMed
21.
go back to reference Bucko AD, Hunt BJ, Kidd SL, Hom R: Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections. Clin Ther. 2002, 24: 1134-1147. 10.1016/S0149-2918(02)80024-8.CrossRefPubMed Bucko AD, Hunt BJ, Kidd SL, Hom R: Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections. Clin Ther. 2002, 24: 1134-1147. 10.1016/S0149-2918(02)80024-8.CrossRefPubMed
22.
go back to reference Grayson ML, Gibbons GW, Habershaw GM, Freeman DV, Pomposelli FB, Rosenblum BI, Levin E, Karchmer AW: Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis. 1994, 18: 683-693.CrossRefPubMed Grayson ML, Gibbons GW, Habershaw GM, Freeman DV, Pomposelli FB, Rosenblum BI, Levin E, Karchmer AW: Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis. 1994, 18: 683-693.CrossRefPubMed
23.
go back to reference Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC: Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med. 2004, 164: 1669-1674. 10.1001/archinte.164.15.1669.CrossRefPubMed Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC: Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med. 2004, 164: 1669-1674. 10.1001/archinte.164.15.1669.CrossRefPubMed
24.
go back to reference Leppard BJ, Seal DV, Colman G, Hallas G: The value of bacteriology and serology in the diagnosis of cellulitis and erysipelas. Br J Dermatol. 1985, 112: 559-567.CrossRefPubMed Leppard BJ, Seal DV, Colman G, Hallas G: The value of bacteriology and serology in the diagnosis of cellulitis and erysipelas. Br J Dermatol. 1985, 112: 559-567.CrossRefPubMed
25.
26.
go back to reference Brown G, Chamberlain R, Goulding J, Clarke A: Ceftriaxone versus cefazolin with probenecid for severe skin and soft tissue infections. J Emerg Med. 1996, 14: 547-551. 10.1016/S0736-4679(96)00126-6.CrossRefPubMed Brown G, Chamberlain R, Goulding J, Clarke A: Ceftriaxone versus cefazolin with probenecid for severe skin and soft tissue infections. J Emerg Med. 1996, 14: 547-551. 10.1016/S0736-4679(96)00126-6.CrossRefPubMed
27.
go back to reference Ware JEJ, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992, 30: 473-483. 10.1097/00005650-199206000-00002.CrossRefPubMed Ware JEJ, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992, 30: 473-483. 10.1097/00005650-199206000-00002.CrossRefPubMed
28.
go back to reference Hunt SM, McEwen J, McKenna SP: Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract. 1985, 35: 185-188.PubMedPubMedCentral Hunt SM, McEwen J, McKenna SP: Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract. 1985, 35: 185-188.PubMedPubMedCentral
Metadata
Title
Development of a Health-Related Quality of Life Questionnaire (HRQL) for patients with Extremity Soft Tissue Infections (ESTI)
Authors
Aric J Storck
Kevin B Laupland
Ronald R Read
Manuel W Mah
John M Gill
Deborah Nevett
Thomas J Louie
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2006
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-6-148

Other articles of this Issue 1/2006

BMC Infectious Diseases 1/2006 Go to the issue